Groot

FONTAINEBLEAU LAS VEGAS TEAMS WITH DAVID GRUTMAN'S GROOT HOSPITALITY TO BRING ICONIC LIV AND LIV BEACH, KOMODO AND PAPI STEAK TO THE STRIP

Retrieved on: 
星期三, 九月 20, 2023
Komodo, Music, Partnership, Food, LIV, Investment, Tomahawk, Einhorn, David Rockwell, Restaurant, Groot, David Grutman, Rolling Stone, EDM, Wine, Las Vegas Strip, Hotel, Nightclub, Fontainebleau Las Vegas, Fontainebleau Miami Beach

LAS VEGAS, Sept. 20, 2023 /PRNewswire/ -- Fontainebleau Las Vegas, the globally anticipated luxury destination brought to life by Fontainebleau Development, has partnered with hospitality entrepreneur David Grutman of Groot Hospitality to bring the nightclub LIV and world-renown restaurants Komodo and Papi Steak to the property when it opens its doors to the world in December 2023, pending regulatory approvals. Additionally, Fontainebleau Las Vegas and Grutman will debut an all-new dayclub concept, LIV BEACH, in Spring 2024, just in time for pool season.

Key Points: 
  • Additionally, Fontainebleau Las Vegas and Grutman will debut an all-new dayclub concept, LIV BEACH, in Spring 2024, just in time for pool season.
  • Both Komodo and Papi Steak will be among the 36 first-to-market food and beverage concepts opening at Fontainebleau Las Vegas.
  • The strategic partnership between Fontainebleau Las Vegas and Groot Hospitality blends the expertise of two industry-changing hospitality leaders.
  • Fontainebleau Las Vegas stands on nearly 25 acres adjacent to the Las Vegas Convention Center District on the Las Vegas Strip.

Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian

Retrieved on: 
星期三, 二月 8, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, International Society on Thrombosis and Haemostasis, Medical director, McMaster University, Atrial fibrillation, Abstract, Oral, Groot, Safety, Intraparenchymal hemorrhage, Division, Patient, Incidence, AF, FXI, Philippine Heart Center, Thrombosis, Research, International Society, Cardiology, Risk, TIA, Duke University, Infarction, Xia, Conference, Principal, FRCPC, Pharmaceutical industry, Stroke, ISTH, Bayer

“Additional research into the combination of FXI inhibition and antiplatelet agents is needed to explore potential treatment options for the future.”

Key Points: 
  • “Additional research into the combination of FXI inhibition and antiplatelet agents is needed to explore potential treatment options for the future.”
    “Through our OCEANIC clinical trial program, Bayer leverages decades of cardiovascular expertise to investigate a potential new class of antithrombotics and explore the potential of asundexian as an additional antithrombotic treatment option across multiple patient populations,” 1-2 said Maria Borentain, M.D., Vice President and Head of Thrombosis and Vascular Disease Clinical Development, Bayer.
  • Effect of factor XIa inhibition with asundexian on recurrent ischemic stroke according to baseline patterns of infarction on brain MRI: PACIFIC-Stroke.6
    Khatri P, Shoamanesh A, Mundl H, et al.
  • Effects of the oral factor XIa inhibitor asundexian on intracranial bleeding among patients with acute non-cardioembolic ischemic stroke: PACIFIC-Stroke randomized trial.
  • 7

ArtVersion Honored With Two Prestigious Awards by the Academy of Interactive & Visual Arts

Retrieved on: 
星期五, 十月 14, 2022
Interactivity, Cultural institution, Culture, Organization, Creative, Art, Principle, Silver, Marketing, W3, Gold, GLOBE, Academy, Video game, Groot

The Virginia A. Groot Foundation is a non-profit organization that provides annual grants to three-dimensional artists around the world.

Key Points: 
  • The Virginia A. Groot Foundation is a non-profit organization that provides annual grants to three-dimensional artists around the world.
  • The w3 Awards celebrates interactive agencies and creators globally and the digital excellence their websites, apps, podcasts, and more exert.
  • Endorsed and judged by the Academy of Interactive and Visual Arts, the w3 Awards are a prestigious honor for innovators, and the two awards received are a testament to the experiences ArtVersion continues to design.
  • The w3 award nominees are carefully judged by a panel of professional experts in the Academy of Interactive and Visual Arts.

SpeeDx and MolGen Announce Partnership for COVID-19 Test Solution

Retrieved on: 
星期三, 六月 30, 2021
Health, Infectious diseases, Genetics, Clinical trials, Research, Science, Biotechnology, Marvel Comics characters, Fictional characters, Automation, Groot, SpeeDx, MolGen, SPEEDX, MOLGEN

View the full release here: https://www.businesswire.com/news/home/20210630005407/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210630005407/en/
    Due to travel restrictions Maarten de Groot, MolGen CEO and Colin Denver, SpeeDx CEO joined a virtual session to officially announce the collaboration that will combine Molgen liquid handling and purpose-built automation with SpeeDx COVID-19 diagnostic solutions - extending a full workflow offering to pathology laboratories.
  • (Photo: Business Wire)
    This partnership capitalises on the existing infrastructure of our two companies and the strength of our synergies, said Colin Denver, SpeeDx CEO.
  • Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology said Maarten de Groot, MolGen CEO.
  • Due to travel restrictions Maarten de Groot, MolGen CEO and Colin Denver, SpeeDx CEO joined a virtual session to officially announce the collaboration that will combine Molgen liquid handling and purpose-built automation with SpeeDx COVID-19 diagnostic solutions - extending a full workflow offering to pathology laboratories.

Your Super Cofounder and CMO, Kristel De Groot enacts innovative "Moon Day" policy ahead of "Moon Balance" product launch

Retrieved on: 
星期四, 六月 25, 2020
Fictional characters, Marvel Comics characters, Human development, Kristel, Groot, Menopause

Created by co-founder and CMO, Kristel De Groot, Moon Balance strives to soothe symptoms from menstruation, menopause and hormonal imbalance.

Key Points: 
  • Created by co-founder and CMO, Kristel De Groot, Moon Balance strives to soothe symptoms from menstruation, menopause and hormonal imbalance.
  • Prior to this release, Your Super enacted a monthly "Moon Day" policy for employees identifying as female.
  • De Groot states, "Like many women, I endeavor to balance work responsibilities, health, my relationship and personal goals.
  • To learn more about Moon Balance and this policy, please visit; Yoursuper.com
    Kristel De Grootis the co-founder and CMO of Your Super.

On Eve of New Decade, EpiVax Re-Pledges Commitment to Improving Health Everywhere

Retrieved on: 
星期五, 十二月 20, 2019
Immunology, Immunogenicity, Groot

PROVIDENCE, R.I., Dec. 20, 2019 /PRNewswire/ --EpiVax, Inc. ("EpiVax"), the home of "fearless science", announces it will renew their company-wide commitment to "improving human health everywhere" in the new decade (2020).

Key Points: 
  • PROVIDENCE, R.I., Dec. 20, 2019 /PRNewswire/ --EpiVax, Inc. ("EpiVax"), the home of "fearless science", announces it will renew their company-wide commitment to "improving human health everywhere" in the new decade (2020).
  • EpiVax has a greater than 20-year tradition of corporate giving to worthy charities, especially those that improve human (or animal) health.
  • Annie De Groot, MD, CEO/CSO of EpiVax, stated, "EpiVax is wholeheartedly committed to improving lives everywhere, through vaccination, developing better medicines for patients, or by providing aid to local organizations.
  • Scientists at EpiVax, led by co-founders Annie De Groot and Bill Martin, lead the field in immunogenicity assessment.

EpiVax Announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports

Retrieved on: 
星期三, 十一月 6, 2019
Medical specialties, Immunology, Branches of biology, Medicine, Computational immunology, Immunogenicity, Antigen, Antibody, Groot, ImmunoGen

PROVIDENCE, R.I., Nov. 6, 2019 /PRNewswire/ --EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" in Scientific Reports, 06 Nov 2019 , a Nature publication.

Key Points: 
  • PROVIDENCE, R.I., Nov. 6, 2019 /PRNewswire/ --EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" in Scientific Reports, 06 Nov 2019 , a Nature publication.
  • Tregitopes are novel peptides first discovered in 2008 in human immunoglobulin by Dr. Anne De Groot and William Martin at EpiVax.
  • EpiVax is encouraged by these findings and looks forward to a continued bright future for the Tregitope program.
  • Scientists at EpiVax, led by co-founders Annie De Groot and Bill Martin, lead the field in immunogenicity risk assessment.

EpiVax Announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports

Retrieved on: 
星期三, 十一月 6, 2019
Medical specialties, Immunology, Branches of biology, Medicine, Computational immunology, Immunogenicity, Antigen, Antibody, Groot, ImmunoGen

PROVIDENCE, Rhode Island, Nov. 6, 2019 /PRNewswire/ --EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" in Scientific Reports, 06 Nov 2019 , a Nature publication.

Key Points: 
  • PROVIDENCE, Rhode Island, Nov. 6, 2019 /PRNewswire/ --EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" in Scientific Reports, 06 Nov 2019 , a Nature publication.
  • Tregitopes are novel peptides first discovered in 2008 in human immunoglobulin by Dr. Anne De Groot and William Martin at EpiVax.
  • EpiVax is encouraged by these findings and looks forward to a continued bright future for the Tregitope program.
  • Scientists at EpiVax, led by co-founders Annie De Groot and Bill Martin, lead the field in immunogenicity risk assessment.

Prestigious World Food Prize Awarded to East-West Seed Founder Simon N. Groot

Retrieved on: 
星期一, 六月 10, 2019
Fictional characters, Awards, Marvel Comics characters, World Food Prize, Norman Borlaug, Groot, IOWA, Kenneth M. Quinn, Mike Pompeo

WASHINGTON, June 10, 2019 /PRNewswire/ -- Today, U.S. Secretary of State Mike Pompeo and President of the World Food Prize Foundation Kenneth M. Quinn announced Simon N. Groot as the 2019 World Food Prize Laureate.

Key Points: 
  • WASHINGTON, June 10, 2019 /PRNewswire/ -- Today, U.S. Secretary of State Mike Pompeo and President of the World Food Prize Foundation Kenneth M. Quinn announced Simon N. Groot as the 2019 World Food Prize Laureate.
  • Known as the "Nobel Prize for Food," the 2019 World Food Prize honors the unique achievements of Simon Groot and his company East-West Seed (EWS) over the past four decades.
  • "Like Dr. Norman Borlaug before him, Simon Groot has dedicated his life to improving the livelihoods of millions around the world," said Kenneth Quinn.
  • Mr. Groot will receive the World Food Prize on October 17, 2019 at the Iowa State Capitol in Des Moines.

DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board

Retrieved on: 
星期四, 四月 4, 2019
Groot

Ferrara will continue his role as a member of DelMar's Board of Directors and serve as the SAB's Chairman.

Key Points: 
  • Ferrara will continue his role as a member of DelMar's Board of Directors and serve as the SAB's Chairman.
  • Dr. John de Groot is a Professor, and Chairman ad interim, in the Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center.
  • de Groot has served as the principal investigator (PI) or co-investigator on multiple funded National Cancer Institute, foundation, and industry-sponsored grants.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.